title: Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up.
abstract: OBJECTIVE
  Compared with placebo, abciximab has been associated with mortality reduction at late follow-up. The TARGET trial was performed to test whether tirofiban and abciximab provide similar efficacy outcomes among patients undergoing non-emergent, stent-based percutaneous coronary intervention. We report here the 1-year mortality of the study population.
  
  
  RESULTS
  In 18 countries at 149 hospitals, 4,809 patients undergoing elective or urgent stent implantation were randomly assigned a bolus and infusion of tirofiban or abciximab. Ischaemic events were assessed at 30 days and 6 months and mortality was assessed at 1 year. We previously reported that abciximab was superior to tirofiban considering the composite rate of death or myocardial infarction at 30 days among all patients and at 6 months among those with an acute coronary syndrome (ACS). At 1-year follow-up death occurred in 46 (1.9%) patients who received tirofiban and 42 (1.7%) patients who received abciximab (hazard ratio 1.10, 95% CI 0.72-1.67; P=0.660). Mortality rates for patients with ACS were 2.3% with tirofiban vs. 2.2% with abciximab (hazard ratio 1.03, 95% CI 0.64-1.67; P=0.897) and those without ACS were 1.4 vs. 1.0% (hazard ratio 1.32, 95% CI 0.56-3.13; P=0.530).
  
  
  CONCLUSIONS
  At 1 year, tirofiban provided a similar level of survival benefit compared with abciximab.
authors.affiliation: Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, Lexington, KY 40536-0200, USA. mukherjee@uky.edu
authors.forename: Debabrata
authors.initials: D
authors.lastname: Mukherjee
authors.forename: Eric J
authors.initials: EJ
authors.lastname: Topol
authors.forename: Michel E
authors.initials: ME
authors.lastname: Bertrand
authors.forename: Steen D
authors.initials: SD
authors.lastname: Kristensen
authors.forename: Howard C
authors.initials: HC
authors.lastname: Herrmann
authors.forename: Franz-Josef
authors.initials: FJ
authors.lastname: Neumann
authors.forename: Steven J
authors.initials: SJ
authors.lastname: Yakubov
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Bassand
authors.forename: Rick R
authors.initials: RR
authors.lastname: McClure
authors.forename: Gregg W
authors.initials: GW
authors.lastname: Stone
authors.forename: Diego
authors.initials: D
authors.lastname: Ardissino
authors.forename: David J
authors.initials: DJ
authors.lastname: Moliterno
mesh_terms: D000077284:Abciximab; D015906:Angioplasty, Balloon, Coronary / Q000379:methods* / Q000401:mortality; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000401:mortality / Q000628:therapy*; D009204:Myocardial Revascularization / Q000379:methods* / Q000401:mortality; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D015607:Stents; D016019:Survival Analysis; D000077466:Tirofiban; D016896:Treatment Outcome; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D014443:Tyrosine; D000077466:Tirofiban; D000077284:Abciximab